Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remibrutinib in adolescents with chronic spontaneous urticaria
2022-502159-78-00Phase 3Authorised
- Sponsor
- Novartis
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 18
01
Overview
Phase 3, randomised, double-blind trial in chronic idiopathic urticaria (CIU) comparing Remibrutinib with Placebo (2 arms). Primary endpoints: Absolute change from baseline in ISS7 at Week 12, Absolute change from baseline in HSS7 at Week 12 and 1 more. Planned start Sep 2023; status: authorised.
02
Drugs
remibrutinib
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on 2022-502159-78-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502159-78-00.